MHRA: policy for handling corporate conflicts of interest
Information about how we handle potential corporate conflicts of interest (COI) between different parts of the Agency.
Documents
Details
This policy outlines the approach to handling potential corporate conflicts of interest (COI) between different parts of the Medicines and Healthcare products Regulatory Agency (MHRA), It sits alongside MHRA staff COI policy. We also publish our annual conflict of interest compliance reports here.
A corporate conflict of interest may arise where one part of the MHRA undertakes work that may require oversight or review by another part of MHRA now or in the future. The risk of an actual COI, or the perception of one, can arise where the MHRA is in a position where its decisions might be – or be seen to be – influenced by its other interests.
Updates to this page
Published 5 June 2014Last updated 30 July 2024 + show all updates
-
Published 'Annual conflict of interest compliance report - 2023/24'.
-
Published updated 'Corporate Conflicts of Interest policy.'
-
Annual conflict of interest compliance report for 2022 added.
-
Uploaded the annual conflict of interest compliance report - 2021
-
Updated Annex C (CPRD annex) of the Corporate Conflicts of Interest Policy and Procedure to include all current types of potential COI. No changes to the main policy and procedure document.
-
Added Annual conflict of interest compliance report - 2020
-
We have published the annual conflict of interest compliance report for 2019.
-
Updated policy for handling conflicts of interest - document put in the standard format and the procedure for raising and dealing with a potential conflict of interest has been made clear in a new ‘procedure’ section.
-
Added the Annual conflict of interest compliance report and Annex A - 2018
-
Added conflict of interest compliance report for 2017
-
Added compliance reports.
-
Updated Conflict of interest policy
-
First published.